Scott Kasner talks to Eivind Berge about the GORE REDUCE trial at ESOC 2017 in Prague. Established superiority of PFO closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new brain infarct.
Content produced and shared with kind authorisation of the European Stroke Organisation (ESO) and the European Stroke Organisation Conference (ESOC 2017).
Share this Video
Related Videos In Stroke
Vida Demarin, CONy 2020 – Statins for Stroke Prevention in Older Generations
Vida Demarin (International Institute for Brain Health, Zagreb, Croatia) kindly took the time to speak with us on the topic of the debate session she participated in: Should statins be given to people over age 80 for stroke prevention? As co-Chair of CONy 2021, she also shared her excitement for the next congress, which will be […]
Arlene Wilkie, ESO-WSO 2020 – Stroke Action Plan for Europe
We were delighted to have an opportunity to hear all about the Stroke Action Plan for Europe from Arlene Wilkie, Director General of the Stroke Alliance for Europe (SAFE). Related useful resources: Stroke Alliance for Europe (SAFE) Economic Impact of Stroke in Europe Questions What are the major challenges in stroke care across Europe and […]
Anna Tancin Lambert, EAN 2020 – Atrial Fibrillation and Cryptogenic Stroke in the NOR-FIB Study
Anna Tancin Lambert (University of Oslo and Department of Neurology Østfold Hospital Trust, Norway) discussed with us exciting interim findings from the international, multicentre, prospective, observational Nordic Atrial Fibrillation and Stroke (NOR-FIB) study, which highlight atrial fibrillation as the hidden cause of cryptogenic stroke (ClinicalTrials.gov Identifier: NCT02937077). Questions 1. What proportion of stroke and transient […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!